News
RHHBF
474.00
NaN%
--
Weekly Report: what happened at RHHBF last week (1019-1023)?
Weekly Report · 19h ago
Reported Sunday, Genentech’s Divarasib Lowers Death Risk 44% In Phase III Krascendo 1 With Fewer TRAE Discontinuations (4.8% Versus 11.7%) Than Sotorasib Or Adagrasib In Previously Treated KRAS G12C NSCLC
Benzinga · 22h ago
Roche lung cancer drug extends survival by nearly six months in late-stage trial
Seeking Alpha · 1d ago
Roche Confirms 2026 Outlook, Expects Mid-Single-Digit Sales Growth At CER, High-Single-Digit Core EPS Growth At CER And Further Dividend Increase In CHF
Benzinga · 5d ago
Roche Q3 Sales Rise 7% YoY At CER; 9M Group Sales Up 6% At CER To CHF 46.5B; Pharmaceuticals Up 7%, Diagnostics Up 4%
Benzinga · 5d ago
Roche – Hansoh cancer drug deal could exceed $14B
Seeking Alpha · 10/19 16:43
Roche pauses German investments over healthcare reforms
Seeking Alpha · 10/19 15:23
Disc Medicine posts late-stage trial win for lead asset developed with Roche
Seeking Alpha · 10/19 11:25
Weekly Report: what happened at RHHBF last week (1012-1016)?
Weekly Report · 10/19 10:23
Roche’s Genentech To Present Pivotal Lung And Breast Cancer Data At ESMO 2026, Highlighting Divarasib Superiority Over Standard Of Care And Giredestrant Efficacy Gains Without Tolerability Or Quality-Of-Life Compromise
Benzinga · 10/19 06:29
Alector: Maintaining "Hold" ABC Platform Transition And GCase Partnership With Roche
Seeking Alpha · 10/19 04:47
FDA Approves Roche’s Enspryng For Adults With Thyroid Eye Disease, First At-Home Subcutaneous Option; SatraGO-2 Proptosis Response 52.9% Vs 23.4% Placebo, SatraGO-1 Missed Primary Endpoint
Benzinga · 10/16 05:47
Recursion: Maintaining 'Hold' On REC-4881 End 2026 Program Update And Collaboration Candidates In Play
Seeking Alpha · 10/15 20:09
Roche signs $1.16B obesity drug deal with China’s Rona Therapeutics
Seeking Alpha · 10/13 08:52
Weekly Report: what happened at RHHBF last week (1005-1009)?
Weekly Report · 10/12 10:29
Reported Saturday, FDA Accepts Genentech’s Vamikibart BLA For Uveitic Macular Edema With Approval Decision Expected By July 2027, Following Phase III Data Showing Sustained Improvements At 52 Weeks
Benzinga · 10/12 08:05
Roche's experimental eye drug shows vision improvements in trials
Seeking Alpha · 10/11 17:13
Roche Wins FDA Nod For Tecentriq Combination In Adjuvant Stage III DMMR Colon Cancer As 36-Month Disease-Free Survival Reaches 86% Versus 76% With Chemotherapy Alone In ATOMIC Trial
Benzinga · 10/09 06:05
Roche taps Chinese startup for drug discovery
Seeking Alpha · 10/08 18:24
Pfizer’s Tukysa regimen approved in U.S. for front-line breast cancer
Seeking Alpha · 10/07 17:30
More
Webull provides a variety of real-time RHHBF stock news. You can receive the latest news about Roche Hldgs Ag through multiple platforms. This information may help you make smarter investment decisions.
About RHHBF
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.